Notícias

The approval gives physicians an alternative to uncoated balloons and Boston Scientific’s paclitaxel-coated device.

Investing.com -- Citi has downgraded Boston Scientific to Neutral from Buy, citing an uncertain recovery path after a string of setbacks this year.

The company said products are moving through its distribution network at or above normal levels as the Marlborough, Mass., company works to fulfill customer orders, reduce backlogs and accelerate the delivery of products.

Boston Scientific (BSX) flagged its inability to meet its near-term financial outlooks amid a "mater

The medical device maker said it is unlikely to meet its full-year sales growth and adjusted earnings targets, and will update investors on Oct. 28

Boston Scientific expects to provide updated full-year 2026 guidance along with its third-quarter results on Oct. 28, 2026.

Medical-device maker Boston Scientific said that it is unlikely to meet its sales growth and earnings expectations for the year, citing a major cyberattack disclosed last month that left it unable to fill orders.

On this episode of Stock Movers: - Novartis (NOVN) shares are lower as it suffered its third clinical-trial setback in a week after a treatment for a rare muscle-wasting disease failed a late-stage study. - Boston Scientific (BSX) shares are moving on news it said that fallout from a cybersecurity incident has impacted its ability to ship its products to customers and will cause the medical devices company to miss its sales growth and earnings estimates for the year. - Intel (INTC) is rising on a report that the company could raise computer chip prices next month.

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock

Despite making progress restoring global operations, the device maker said in a securities filing that it is unlikely to meet third-quarter and full-year sales and earnings forecasts.

Boston Scientific (BSX) identified a cybersecurity incident affecting certain information technology

Boston Scientific stock falls as the medical device maker says a recent cyberattack may make it hard to hit quarterly and full-year guidance targets.

Boston Scientific said it likely won’t meet its financial guidance due to the cyberattack that has disrupted its operations, sending shares of the medical-technology company down sharply in premarket trading.

Boston Scientific said it likely won’t meet its financial guidance due to the cyberattack that has disrupted its operations, sending shares of the medical-technology company down sharply in premarket trading.

Sept 8 () - Boston Scientific said ‌on Tuesday a ‌cybersecurity incident that disrupted ​manufacturing and order shipments globally is likely to ‌have ⁠a material impact on its ⁠third-quarter and full-year 2026 results. The ​medical device ​maker ​is unlikely ‌to meet its previously issued third-quarter and full-year sales and adjusted profit ‌forecast, it ​said ​in ​a regulatory ‌filing.

Protolabs (PRLB) CEO and President Suresh Krishna joins Market Domination's Josh Lipton to discuss the Trump administration considering additional semiconductor tariffs and the American reshoring of manufacturing.

The Standard & Poor's 500 index edged up 0.5% this week amid stronger-than-expected quarterly report

Alabama’s attorney general wants answers after OpenAI models went rogue during a test run and hacked a real-world company. The state this week subpoenaed OpenAI and CEO Sam Altman, looking for details about the incident as well as every employee involved, plus those who raised safety concerns. On Wednesday, the company released a lengthy report that addressed some, but not all, of the issues Alabama raised.

On Aug. 26, 2026, a cyberattack halted order processing and shipping at the medical device maker, leaving investors uncertain about the speed of recovery and near-term shipment delays.

Shares of medical-device maker Boston Scientific are down 4.5% Wednesday on concerns that a cyber-attack against the company could hurt near-term revenue. The incident, which Boston Scientific said it detected Tuesday, caused a network outage and disruption to operations, including the ability to process and ship orders, a spokeswoman said. Evercore ISI analysts noted that a similar cyberattack against medical-device maker Stryker in March took about three weeks for the company to recover from.

Stocks wavered at the opening bell on Wednesday as investors assessed fresh inflation data and upcoming earnings from AI bellwether Nvidia.

(Updates with economic data, recent oil price changes, world markets' overview, and corporate stock

Aug 26 (Reuters) - Boston Scientific said on Wednesday that a cybersecurity incident had disrupted global operations, including some information systems used to process and ship customer orders.

WATCHMAN and Electrophysiology headwinds force guidance cut despite solid organic growth.

Boston Scientific (BSX) reported Q2 revenue and EPS that beat expectations but lowered its full-year

BSX faces WATCHMAN and EP pressures as management cuts outlook while highlighting cost savings and new product catalysts for future growth.

Boston Scientific recently reported its second-quarter 2026 results, showing sales of US$5,442 million and net income of US$907 million, alongside issuing a recall of its Rapid Refill Continuous Injection System and initiating a multi-year global restructuring plan aimed at cost efficiencies. While the company raised full-year 2026 net sales growth expectations to approximately 5.5%–6.5%, it also outlined a restructuring program costing up to US$800 million and targeting around US$500...

Moby summary of Boston Scientific Corporation's Q2 2026 earnings call

Boston Scientific (NYSE:BSX) reported second-quarter 2026 revenue growth at the high end of its guidance range and adjusted earnings per share above expectations, but lowered its full-year outlook as it faces slowing demand in its WATCHMAN left atrial appendage closure business and increased competi

Boston Scientific Corp (BSX) reports a robust Q2 with 7% organic sales growth and a 15% increase in adjusted EPS, despite challenges in some segments.